CTAG1A
Cancer/testis antigen 1
Also known as: CT6.1, CTAG, CTAG1, CTAG1B, CTG1B_HUMAN, ESO1, LAGE2A, LAGE2B, NY-ESO-1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P78358
- Gene
- CTAG1A
- Ensembl
- ENSG00000268651
- Chromosome
- X
- Canonical length
- 180 aa
- Protein class
- Cancer-related genes, Predicted intracellular proteins
- Subcellular location
- Golgi apparatus,Vesicles
OverviewNCBI Gene
The protein encoded by this gene is a tumor cell antigen found in various types of cancers, which makes it a good candidate for a cancer vaccine. This gene is also highly expressed in normal ovary and testis tissues. An identical copy of this gene is found on the same chromosome. [provided by RefSeq, Dec 2015]
Canonical amino-acid sequenceUniProt
180 residues, UniProt reviewed canonical sequence.
>P78358|CTAG1A
1 MQAEGRGTGG STGDADGPGG PGIPDGPGGN AGGPGEAGAT GGRGPRGAGA ARASGPGGGA
61 PRGPHGGAAS GLNGCCRCGA RGPESRLLEF YLAMPFATPM EAELARRSLA QDAPPLPVPG
121 VLLKEFTVSG NILTIRLTAA DHRQLQLSIS SCLQQLSLLM WITQCFLPVF LAQPPSGQRRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CTAG1A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.57
- Highest tissue expression
- 7.6 nTPM
Expression across tissuesHPA
Tissue
- testis: 7.6 nTPM
- cerebellum: 0.3 nTPM
- blood vessel: 0.1 nTPM
- breast: 0.1 nTPM
- cerebral cortex: 0.1 nTPM
- midbrain: 0.1 nTPM
Single-cell type
- adipocytes: 0 nCPM
- adrenal cortex cells: 0 nCPM
- adrenal medulla cells: 0 nCPM
- alveolar cells type 1: 0 nCPM
- alveolar cells type 2: 0 nCPM
- b-cells: 0 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 0.4 nTPM
- pons: 0.4 nTPM
- medulla oblongata: 0.3 nTPM
- thalamus: 0.3 nTPM
- amygdala: 0.1 nTPM
- basal ganglia: 0.1 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CTAG1A.
Disease | ImmuneIEDB
Conditions an epitope on CTAG1A was assayed in.
- skin melanoma T cell
- ovarian cancer T cell
- melanoma B and T cell
- gastric adenocarcinoma T cell
- hepatocellular carcinoma T cell
- lung adenocarcinoma T cell
- prostate cancer B and T cell
- stomach cancer T cell
- esophageal cancer T cell
- lung non-small cell carcinoma T cell
- cancer T cell
- glioblastoma T cell
- cholangiocarcinoma T cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against CTAG1A are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for CTAG1A from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
17 publications
- A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
1998 · J Exp Med · RCR 11.2 · 579 citations - Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
2015 · J Transl Med · RCR 2.6 · 80 citations - NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
2016 · J Gastroenterol · RCR 2 · 69 citations - Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
2020 · Cancer Biomark · RCR 1.2 · 23 citations - Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers.
2020 · Ann Gastroenterol Surg · RCR 1.1 · 22 citations
Show 12 more
- Six autoantibodies as potential serum biomarkers of hepatocellular carcinoma: A prospective multicenter study.
2020 · Int J Cancer · RCR 1 · 19 citations - Tumor-associated autoantibodies in ESCC screening: Detecting prevalent early-stage malignancy or predicting future cancer risk?
2021 · EBioMedicine · RCR 0.8 · 12 citations - NY-ESO-1 antigen-antibody interaction process based on an TFBG plasmonic sensor.
2023 · Biomed Opt Express · RCR 0.7 · 5 citations - Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
2008 · PLoS One · RCR 0.7 · 35 citations - Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group.
2017 · J Thorac Oncol · RCR 0.4 · 10 citations - Expression and immunogenicity of NY-ESO-1 in colorectal cancer.
2017 · Exp Ther Med · RCR 0.3 · 9 citations - Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis.
2015 · Int J Clin Exp Pathol · RCR 0.3 · 9 citations - Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.
2024 · Cancer Res Commun · RCR 0.3 · 3 citations - Combination of autoantibodies against NY-ESO-1 and viral capsid antigen immunoglobulin A for improved detection of nasopharyngeal carcinoma.
2014 · Oncol Lett · RCR 0.3 · 9 citations - Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma.
2017 · Oncotarget · RCR 0.2 · 6 citations - Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status.
2017 · Virol J · RCR 0 · 1 citations - Erratum to: NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
2016 · J Gastroenterol
Reference: B cellIEDB
2 publications
- Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
2020 · Cancer Immunol Res · RCR 2.5 · 63 citations - Autoantibody Landscape in Patients with Advanced Prostate Cancer.
2020 · Clin Cancer Res · RCR 0.6 · 14 citations
Reference: T cellIEDB
32 publications
- Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
1998 · J Exp Med · RCR 10.7 · 570 citations - Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.
2014 · Hepatology · RCR 7.8 · 298 citations - Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
2021 · Immunity · RCR 5.3 · 114 citations - Tumor antigen-specific CD8+ T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer.
2017 · Cell Immunol · RCR 2.3 · 77 citations - Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma.
2020 · Cancer Immunol Res · RCR 1.9 · 51 citations
Show 20 more of 32 total
- Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.
2018 · Proc Natl Acad Sci U S A · RCR 1.8 · 68 citations - Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.
2016 · Oncoimmunology · RCR 1.4 · 52 citations - Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide.
2018 · Nat Commun · RCR 1.4 · 43 citations - Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells.
2020 · J Immunother Cancer · RCR 1.4 · 39 citations - Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.
2013 · Cancer Immunol Res · RCR 1.3 · 53 citations - Impact of Cysteine Residues on MHC Binding Predictions and Recognition by Tumor-Reactive T Cells.
2020 · J Immunol · RCR 1 · 26 citations - Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
2014 · Cancer Immunol Res · RCR 0.9 · 40 citations - Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.
2014 · Cancer Immunol Res · RCR 0.8 · 37 citations - Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.
2013 · Int J Cancer · RCR 0.7 · 27 citations - HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer.
2014 · Invest New Drugs · RCR 0.7 · 24 citations - Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.
2016 · J Immunother Cancer · RCR 0.7 · 25 citations - Fusion of NY-ESO-1 epitope with heat shock protein 70 enhances its induced immune responses and antitumor activity against glioma in vitro.
2024 · Transl Cancer Res · RCR 0.6 · 4 citations - In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.
2017 · J Biol Chem · RCR 0.6 · 22 citations - Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides.
2024 · J Immunother Cancer · RCR 0.6 · 5 citations - Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
2020 · Elife · RCR 0.6 · 17 citations - CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg.
2013 · Cancer Immunol Res · RCR 0.5 · 22 citations - NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma.
2018 · Cancer Immunol Immunother · RCR 0.5 · 13 citations - Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1.
2013 · PLoS One · RCR 0.5 · 12 citations - Immune responses against tumour-associated antigen-derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients.
2018 · Liver Int · RCR 0.4 · 14 citations - Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
2018 · Cancer Immunol Res · RCR 0.4 · 14 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CTAG1A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CTAG1A as an antibody target. Whether an autoantibody or antibody against CTAG1A could matter depends on whether native CTAG1A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CTAG1A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label CTAG1A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...